Patient-centric predictive modeling: AI-ML
Among the billions of individual data points and genetic interactions, there exists an infinite number of possible pathways we could investigate. Given the complexity of this data, we need more advanced tools to help us analyse it at scale. That’s where AI comes in, to help us separate the relevant from…
Annual Report 2022
Approximately 70% of our targets in research are genetically validated
The success of our R&D rests not just on finding new treatments, but on getting better at how we find them. The key to that is combining human genetics, genomics and advanced technologies to make better predictions about who a treatment might work for, and…
GlaxoSmithKline (GSK) is creating a data-focused culture and a global machine-learning team.
Earlier this year, GSK executives explained to Fierce Biotech why they felt the company’s push into oligonucleotides was such a good fit. | Earlier this year, GSK executives explained to Fierce Biotech why they felt the company’s push into oligonucleotides was such a good fit. Now, the British Big Pharma has added further depth to…
Onc.AI, a medical technology company developing a novel digital clinical management solution focused on immuno-oncology, announced today it has closed
technology to develop innovative medicines
PUBLISHED :…
GSK’s new chief scientific officer Tony Wood is building on the precision medicine approach by partnering with Tempus to accelerate cancer drug trials and improve the firm’s R&D productivity.
GSK’s new chief scientific officer Tony Wood is building on the precision medicine approach by partnering with Tempus to accelerate cancer drug trials and improve the firm’s R&D productivity.
Collaboration leverages one of world’s largest sources of de-identified patient data to accelerate drug discovery, initially in oncology
Access will enable GSK to improve clinical trial design, speed up enrolment and identify drug targets
GSK plc (LSE/NYSE: GSK) and Tempus, a US-based precision medicine company, have entered into a three-year collaboration agreement that provides GSK…
The partnership will apply AI and computation to drug discovery process. Credit: Myriam Zilles from Pixabay.
…
GlaxoSmithKline is ramping up its use of artificial intelligence and recruiting 80 AI specialists by the end of 2020 as it turns to cutting-edge computing to develop medicines of the future. However, the UK’s largest drugmaker by revenue is struggling to hire enough AI researchers and engineers from areas such as Silicon Valley and is…